International Speakers

Dr. Robert Kerbel

Dr. Robert Kerbel,
Canada

Dr. Nicolas Andre

Dr. Nicolas Andre,
France

Dr. Francesco Bertolini

Dr. Francesco Bertolini,
Italy

Dr. Pan Pantziarka

Pan Pantziarka, PhD,

Pan Pantziarka

Pan Pantziarka, PhD,

Dr Pan Pantziarka, PhD, is a scientist working for the Anticancer Fund, primarily in the areas of drug repurposing and related topics. He is the coordinator of the Repurposing Drugs in Oncology (ReDO) project, an international collaboration between Belgium-based Anticancer Fund and the US not-for-profit GlobalCures. In addition to publishing papers on specific non-cancer drugs with the potential to be repurposed for oncological use, the ReDO project is engaged on cancer policy work related to drug licensing and similar issues.


Pan Pantziarka is also the co-founder and Chairman of the George Pantziarka TP53 Trust, a UK-based patient advocacy and support organisation for sufferers of the rare genetic cancer condition Li Fraumeni Syndrome (LFS). In addition to patient advocacy, he has published a number of peer-reviewed papers on LFS.

Recent key publications include:
Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.Ecancermedicalscience. 2016 Jan 11;10:610. doi: 10.3332/ecancer.2016.610. eCollection 2016. PMID: 26823679

Sukhatme V, Bouche G, Meheus L, Sukhatme VP, Pantziarka P.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.Ecancermedicalscience. 2015 Aug 27;9:568. doi: 10.3332/ecancer.2015.568. eCollection 2015.PMID: 26435741

Pantziarka P.Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche.Ecancermedicalscience. 2015 May 21;9:541. doi: 10.3332/ecancer.2015.541. eCollection 2015.PMID: 26082798

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?Future Oncol. 2015;11(2):181-4. doi: 10.2217/fon.14.244. PMID: 25591833

Dr. Sterba Jaroslav

Dr. Sterba Jaroslav,
Czech Republic

Dr. Kieran Mark

Dr. Kieran Mark,
USA

Dr. Antonella Palazzo

Dr. Antonella Palazzo,
Italy

Dr. Eddy Pasquier

Dr. Eddy Pasquier
France

Dr. Giselle Saulnier Sholler

Dr. Giselle Saulnier Sholler, USA

Dr. Yuval Shaked

Dr. Yuval Shaked,
Israel

Dr. David J. Waxman

Dr. David J. Waxman,
USA

Dr. David J. Waxman

Dan G. Duda,
DMD, PhD

Nicolas Andre

Dan G. Duda

Dan G. Duda, DMD, PhD
Translational Research Director for GI Radiation Oncology
Associate Professor of Tumor Biology, Harvard Medical School
Associate Investigator, Edwin L. Steele Laboratories for Tumor Biology
Department of Radiation Oncology, Massachusetts General Hospital

Dan G. Duda obtained his DMD from the University of Medicine Iasi, Romania in 1993, and earned his PhD in Medical Sciences (GI Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, he joined as a Postdoctoral Fellow the Steele Laboratories for Tumor Biology in the Department of Radiation Oncology at Massachusetts General Hospital and Harvard Medical School


in Boston. After becoming junior Faculty member (Instructor) in 2004, he rose through the ranks to Associate Professor of Tumor Biology in 2012. His current research efforts focus on the role of the interactions between locally derived stroma (tumor-associated vessels, fibroblasts) and distant stroma (inflammatory cells) with cancer cells in tumor progression and resistance to treatment. The goal is to identify new targets for therapy and biomarkers of response. While these translational studies include multiple tumor types, the main areas of focus are metastatic or advanced pancreatic, liver and prostate carcinoma, all of which remain intractable diseases. He has authored over 160 publications so far, of which 90 are original reports, including articles in Nature, Nature Genetics, Nature Medicine, Cell, Cancer Cell, and Journal of Clinical Oncology. He has been invited to present these studies at over 120 local, national and international meetings, including in plenary sessions and as a keynote speaker. For his work, Dr. Duda received several awards from AACR, CRI, IASGO and MGH. He is an Honorary Member of the Academy of Medical Sciences of Romania since 2012. He has served as a panel member for multiple scientific expert meetings worldwide. His research is currently supported by grants from the US National Cancer Institute, Massachusetts General Hospital ECOR, Andrew L. Warshaw, MD, Institute for Pancreatic Cancer and The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, as well as by partnerships with Industry (Merrimack Pharma and HealthCare Pharma). He is the Head of the IASGO Cancer Research Section since 2013, and the Secretary General of the IASGO in 2015. In 2016, he was appointed as the Director of Translational Research in Gastrointestinal Cancer in the Department of Radiation Oncology at MGH Cancer Center.

Dr. Yuval Shaked

Dr. Lisa Hutchinson

lisa_hutchinson

Dr. Lisa Hutchinson, BSc, PhD

Chief Editor
Nature Reviews Clinical Oncology

Lisa obtained a first class honours BSs degree in Biochemistry from University College London, and received her PhD from the Institute of Cancer Research, London, under the supervision of Dr Michael J. Fry, where her research focused on the biochemical analysis of components of the Wg/Wnt signalling pathway in breast cancer. Lisa then left the bench to pursue her career in publishing, and in 1999 joined Current Science Ltd as Assistant Editor of the journal Breast Cancer Research. She was promoted to the Editor after 1 year. In 2002, she joined Wells Healthcare Limited as Senior Editor working on a number of projects in the fields of hepatology, diabetes, chronic wound care, and drug addiction. Lisa joined the Nature Reviews department in 2004 and has been the Chief Editor of Nature Reviews Clinical Oncology since that time.

Dr. David J. Waxman

Prof. Richard Sulivan

richard_sulivan

Prof. Richard Sulivan

Director, Institute of Cancer Policy &
KHP Integrated Cancer Centre Global Health Work. 
Kings College London

Professor Richard Sullivan is Director of the Institute of Cancer Policy and KHP Integrated Cancer Centre global health work. He also teaches on the conflict and security module of the Global Health iBSc and is the cancer lead for the King’s Sierra Leone Partnership.

Richard’s research programmes extend from the public policy of global cancer, to the development of care and research systems in emerging economies and the development of public health systems, particularly NCDs, in high-risk conflict areas focusing on DR Congo, Afghanistan & Libya.

Richard is a Visiting Professor (Faculty of Medicine) at Universidad Catolica, Santiago de Chile, Washington University and a senior fellow at the International Prevention Research Institute, Lyon. He was formally Clinical Director of Cancer Research UK, including leading their global health policy research and was past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security think-tank where he specialised in the security implications of global health and bioweapons.

Dr. David J. Waxman

Dr. Sébastien Benzekry

sebastien_benzekry

Dr. Sébastien Benzekry

Email: benzekry@phare.normalesup.org

Address: INRIA Bordeaux-Sud Ouest
Institut de Mathématiques de Bordeaux
UMR CNRS 5251
University of Bordeaux
351 cours de la Libération
33405 Talence Cedex, France

Robert Kerbel

Robert Kerbel

Senior Scientist
University of Toronto
Sunnybrook Health Sciences Centre 
2075 Bayview Avenue, S-Wing, Room S217
Toronto, ON  M4N 3M5 CANADA

Perturbing Angiogenic Pathways as a Novel Therapeutic Modality.

Dr. Kerbel's research is focused in the area of tumor angiogenesis and antiangiogenic therapy. In this regard, one of the most significant developments in medical oncology over the last five years has been the approval of three different antiangiogenic drugs


for the treatment of a number of human cancers, e.g. breast, colorectal, renal, and hepatocellular carcinoma. This includes bevacizumab (Avastin), the humanized anti-VEGF monoclonal antibody which is now undergoing evaluation in almost 400 clinical trials around the world. Despite the successes of antiangiogenic drugs, including bevacizumab, remarkably little is known about how these drugs actually work as anti-cancer agents.

The reason for the counterintuitive property of an antiangiogenic drug enhancing the efficacy of chemotherapy is unknown and is a subject of investigation in our laboratory as well as a number of others around the world. In addition, the best way to administer chemotherapy with an antiangiogenic drug remains to be determined. Another major question in the field is how to determine the optimal biologic dose for antiangiogenic drugs and to monitor their activity in vivo.

Dr. Kerbel is also pioneering a concept known as 'metronomic' chemotherapy (where chemotherapy is given at close regular intervals at low doses with no prolonged drug-free breaks) as an exciting and novel new way to combine chemotherapy with a targeted antiangiogenic drug such as bevacizumab, for the treatment of advanced metastatic disease. We have developed a number of new models of advanced metastatic disease in immune deficient mice involving human tumor cell lines, including breast, ovarian, and hepatocellular carcinoma, as well as malignant melanoma. These studies have evolved in a new research initiative, namely, the development of models of spontaneous brain metastases and their use to study the biology and treatment of such lesions. Finally, our group is at the forefront of studying circulating cellular and molecular surrogate biomarkers in peripheral blood for antiangiogenic drugs and/or metronomic low-dose chemotherapy which can help determine the optimal biologic dose to be used for such drugs/treatments.

Nicolas Andre

Nicolas Andre

MD, PhD
Pediatric Oncologist,
Department of Hematology & Pediatric Oncology in the "Hopital pour Enfants de La Timone" in Marseille, France

Dr. Nicolas André is a pediatric oncologist in the Department of Hematology & Pediatric Oncology in the "Hôpital pour Enfants de La Timone" in Marseille, France, where he is in charge of the pediatric oncology early clinical trial unit.

He is also a member of the CRO2-UMR INSERM 911- (Centre de Recherche en OncologieBiologiqueetOncopharmacologie) in Marseille.


He is the current chair of the SFCE pharmacology group.

He gained his medical degree in 2002 and a doctoral degree in 2003. He is the former president of the "Société Francophone de Recherche en Pédiatrie".

Currently, his research interests and topics include pediatric brain tumors, pediatric rare tumors and pharmacology (new anticancer agents, metronomic chemotherapy). His has developed over the years an international expertise in metronomic chemotherapy has given lectures on metronomics worldwide.

The use of metronomic chemotherapy in "his" own patients has convinced him that this tool could be valuable for children in developing countries. He then launched Metronomics Global Health Initiative as the structure that could promote the development of metronomics with the highest standards and pave the way for new global strategies to fight cancer in developing countries.

He is the author of over 120 peer reviewed publications and book chapters.

Francesco Bertolini

Francesco Bertolini

Director of the laboratory of Hematology-Oncology
European Institute of Oncology, Milan, Italy
francesco.bertolini@ieo.it

Francesco Bertolini, MD, PhD is a clinician-scientist currently serving as the director of the laboratory of Hematology-Oncology at the IEO. Throughout his scientific career in Italy, at the Cardeza Foundation for Hematological Research at Thomas Jefferson University in Philadelphia and in the University of Amsterdam, Dr Bertolini has contributed to a variety of facets of cancer translational research in the angiogenesis and in the hematopoietic stem cell fields.


Dr Bertolini's research has generated the first cord blood stem cell bank in Europe, innovative preclinical models of neoplastic diseases, novel surrogate biomarkers for the prediction of anti-angiogenic drug efficacy in cancer patients and clinical trials where anti-angiogenic drugs are used in association with low-dose chemotherapy.

Gauthier Bouche

Gauthier Bouche

Medical Director
Anticancer Fund
Brussels Area, Belgium

Gauthier holds a MD from the University of Poitiers, France and a MPH from the University of Bordeaux, France. After a few years as assistant professor in public health, epidemiology and clinical research at the University of Poitiers, his main focus is now on clinical research in cancer. He serves as the Medical Director of the Anticancer Fund.

He is responsible for the content of the "cancers" and "guides for patients-cancer types" sections of this website.

Sterba Jaroslav

Sterba Jaroslav

MD, PhD
Professor of Oncology, &Head of Pediatric Oncology Dpt.,
University Children's Hospital Brno, Czech Republic
Vice-Dean, Faculty of Medicine, Masaryk University Brno, Cz
Chairman of the NHL committee of the International BFM group

Pr Sterba is a pioner in metronomic chemotherapy in children and has published the first European pediatric trial (COMBAT) in 2006 and organized the first Workshop in Metronomic and differentiating therapies in children and AYA in Brno in 2008. He has since improved the COMBAT protocol and is still engaged in the development of metronomic chemotherapy in children.

He is Member of the Children's Oncology Group (COG) (international associate member); European Bone and Marrow Transplant Group (EBMT); and SIOP.

Kieran, Mark

Kieran Mark

W.,M.D.,Ph.D.
Director, Pediatric Medical Neuro-Oncology
Institute Physician 
Associate Professor of Pediatrics, Harvard Medical School
Dana-Farber/Boston Children's

Dr. Kieran received his PhD in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. He completed postgraduate training in molecular biology at the Pasteur Institute in Paris.


After a pediatric residency in Montreal at McGill University, he received postdoctoral education at Boston Children's Hospital (BCH).

In 1998, he became director of Pediatric Medical Neuro-Oncology at Dana-Farber/Boston Children's. In addition to his role in the treatment of patients with brain tumors and the development of novel agents for the treatment of recurrent tumors, he continues to focus his laboratory efforts on angiogenesis agents from work he started in the laboratory of the late Dr. Judah Folkman.

Recent Awards

  • America's Top Doctors for Cancer, Castle Connolly, 2014
  • America's Top Physicians, Showmark, 2014
  • Marquis Who's Who in Medicine and Healthcare, 2014
  • Science and Medicine Award, Progeria Research Foundation, 2014
  • Top Doctors in Boston, Boston Magazine, 2014

Antonella Palazzo

Antonella Palazzo

MD
Divisione di Senoloogia Medica
IEO Instituto Europeo di Oncologia (European Institute of Oncology)
Via Ripamonti 435 – 20141 Milano. Italy

Role of tumor infiltrating lymphocytes in patients with triple-negative breast cancer receiving metronomic chemotherapy: Gianni Bonadonna Breast Cancer Research Fellowship.

Giselle Saulnier

Giselle Saulnier

Director of Pediatric Oncology Research & Head of the Pediatric Oncology Translational Research Laboratory
Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
Associate Professor, Michigan State University College of Human Medicine
Chair of the Neuroblastoma & Medulloblastoma Translational Research Consortium (NMTRC)

After completing her Residency and Pediatric Hematology/Oncology Fellowship at Brown University, Providence and Hasbro Children's Hospital/Rhode Island Hospital.


Pr. Sholler became assistant Professor of Pediatrics, Division of Pediatric Hematology/Oncology University of Vermont, Burlington VT and worked as a Guest Researcher in Pediatric Oncology Branch of the NCI, NIH in Bethesda, MD. She then joined the Van Andel Research Institute and the University of Vermont.

Pr. Sholler is the author of 20 publications and is currently working on a Trial using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent tumour within the NMTCR.

She is the member of several associations including the AACR, ASCO, COG and SIOP20

Yuval Shaked

Yuval Shaked

Assistant Professor of Molecular Pharmacology
Hebrew University, Israel

The double-edged sword of cancer therapy: Anti-cancer therapies, including chemotherapy, radiation, surgery and targeted drugs, often generate host responses that contribute to tumor outgrowth and relapse despite an initial successful therapy outcome. Tumor relapse due to host effects is attributed to angiogenesis, tumor cell repopulation, dissemination from the primary location, and seeding at metastatic sites.

The therapy triggers host cell colonization at the primary tumor site and secretion of cytokines and growth factors that,


in turn, promote tumor relapse and resistance to therapy.  In my laboratory we study the host responses generated by a variety of anti-cancer drug therapies and their attendant clinical implications.

avid J. Waxman

David J. Waxman

Ph.D.
Professor of Cell and Molecular Biology, Department of Biology and Bioinformatics Program, Boston University
Professor of Medicine, Boston University School of Medicine

Cancer therapy, angiogenesis and the immune system – Recent advances in our understanding of host-tumor interactions have provided new opportunities to improve cancer treatment using drugs that target the tumor vasculature and inhibit tumor blood vessel development (angiogenesis).


This project aims to develop novel, more effective approaches to combining angiogenesis inhibitors with traditional cancer chemotherapeutics, whose access to the tumor can be substantially diminished when tumor blood flow is interdicted by anti-angiogenesis. Other goals include the use of regular, 'metronomic' drug delivery schedules to elicit persistent DNA damage leading to activation of a potent, anti-tumor innate immune response, and elucidation of the role of cancer stem cells (tumor-initiating cells) in cancer development, angiogenesis, and drug responsiveness.

Chief Guest for the Inaugural Function

Dr. Anil Kakodkar

Padmavibhushan Dr. Anil Kakodkar, Chief Guest

anil_kakodkar

Padmavibhushan Dr. Anil Kakodkar, Chief Guest

Member, AEC &
INAE Satish Dhawan Chair of Engineering Eminence.
Bhabha Atomic Research Centre
Scientist, Researcher, Educationist & Social Activist. Administrator.

Dr. Anil Kakodkar, the distinguished nuclear scientist of India, obtained his BE (Mech. Engineering) degree from the Bombay University in 1963 and M.Sc. in the Experimental Stress Analysis from the Nottingham University in 1969. He joined the Bhabha Atomic Research Centre (BARC) in 1964, following the one year post graduate Training with top rank in Nuclear Science and Technology in the then Atomic Energy Establishment. He became the Director of BARC in the year 1996 and was the


Chairman, Atomic Energy Commission and Secretary to the Government of India, Department of Atomic Energy, during the years 2000 -2009. Currently he is DAE Homi Bhabha Chair Professor at BARC and also Chairman of Rajiv Gandhi Science and Technology Commission of India. Dr. Kakodkar devotes his time primarily on issues related to energy, education and societal development. He is associated with various national and international science institutes. For his outstanding contribution in the field of science & technology, he has been conferred with prestigious Padma Vibhushan award in the year 2009 by the Government of India.

Partners and Sponsors

Contact

  • R.R. Choksi Auditorium,
    Tata Memorial Hospital,
    Parel, Mumbai. India.
  • event@metronomicsmumbai.com
  • Dr. Shripad Banavali - 9820074514
  • Dr. Vijay Patil - 9869382266
  • Ms. Leena Walvankar - 9773862355

Copyrights © Metronomics Mumbai 2016 | Complete Web & IT Solutions by NWDCo